Inclusion Criteria:

- Patient with first liver transplantion or retransplantation since more than 6 months:
with a post-transplant lapse of time of 2 to 10 years and showing one of the
following adverse effects of ICN:

- Renal insufficiency defined by a creatinine clearance <50ml/mn (calculated or
estimated according to the Cockcroft formula)

- Arterial hypertension not controlled by an anti-hypertensive bitherapy

- Diabetes mellitus (fasting glycaemia >7.0mmol/l), whether treated or not

- Neuromuscular toxicity

- Immunosuppression by cyclosporine or tacrolimus and MMF

- Hepatic biopsy performed within the 6 months preceding the inclusion for the patients
with a post-transplant period of <5 years and in the 12 months preceding the
inclusion for patients with a post transplant period of >5 years.

Exclusion Criteria:

- Acute rejection within the 6 months preceding the screening

- Previous history of cortico-resistant rejection

- Chronic rejection

- Significant ductopenia (absence of inter-lobule biliary canals in more than 30% of
the portal tracts) on the pre-screening biopsy.

- Existence of a pre-transplantation diabetes mellitus.

- Liver transplantation for auto-immune hepatitis or primary sclerosing cholangitis

- Patients transplanted for viral C cirrhosis with reinfection lesions of the
transplanted organ, rendering treatment by ribarivine + interferon conceivable in the
year following inclusion.

- Counter-indications to MMF (anaemia, leucopenia)

- Immunosuppression by sirolimus, everolimus, azathioprine or corticoids